Hypertension Trial, Recruiting NCT06877234 Sponsor: Shenzhen Pulsecare Medical Technology Co., Ltd. Condition: Hypertension
Back to Hypertension

Hypertension Trial, Recruiting

NCT06877234
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 to 65 years old
  • People diagnosed with essential hypertension (high blood pressure that is not caused by another medical condition)
  • People who have been consistently taking 2 or more blood pressure medications at standard doses for at least 4 weeks before joining, and whose blood pressure readings meet specific levels: a clinic reading of systolic (top number) between 150–180 mmHg and diastolic (bottom number) at or above 90 mmHg, AND a systolic reading of 135–170 mmHg on a 24-hour blood pressure monitoring test
  • People who have had high blood pressure for more than 6 months
  • People whose kidney arteries, as measured by a specialised scan (CTA), are at least 3 mm wide and at least 20 mm long
  • People (or their legal representative) who have signed a written consent form approved by an ethics committee before screening begins

Who may not be able to join:

  • People who have Type 1 diabetes, or Type 2 diabetes that is not well controlled (based on a specific blood test result)
  • People whose kidneys are not filtering blood well enough, based on a standard kidney function measurement (eGFR below 45 mL/min/1.73 m²)
  • People who have previously had a pacemaker or an implantable heart device (ICD) fitted
  • People who have had a heart attack, fainting episode, brain bleed, or stroke within the 6 months before signing the consent form
  • People with severe narrowing of a heart valve
  • People with conditions that could interfere with accurate blood pressure readings, such as severe blood vessel disease, a large aortic aneurysm, or blood disorders like haemophilia, very low platelets, or severe anaemia
  • People who have sleep apnoea
  • People who are pregnant, breastfeeding, or planning to become pregnant within the next year
  • People with another serious illness where life expectancy is less than 12 months
  • People who are currently participating in another clinical trial that has not yet finished
  • People whose kidney artery scan shows more than 50% narrowing in either kidney artery, or shows an aneurysm (bulge) in either kidney artery (confirm with trial site)
  • People who have previously had a procedure carried out on their kidney arteries
  • People the trial investigators consider unsuitable for any other reason (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 16 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 02081332199

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Shenzhen Pulsecare Medical Technology Co., Ltd.
Registry
ClinicalTrials.gov
Start date
8 August 2024
Est. completion
1 December 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

The change in the average daytime systolic blood pressure two months after the operation; Major adverse events within 30 days after the operation

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov